VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Newly diagnosed and untreated sputum smear         │ Newly diagnosed and untreated sputum smear         │     100 │
│ positive tuberculosis patient                      │ positive tuberculosis patient                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pulmonary lesion consistent with TB by             │ Pulmonary lesion consistent with TB by             │     100 │
│ radiological examination                           │ radiological examination                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Positive sputum culture, identification of         │ Positive sputum culture, identification of         │     100 │
│ bacterial type confirmed Mycobacterium             │ bacterial type confirmed Mycobacterium             │         │
│ tuberculosis. MGIT drug sensitivity test (DST)     │ tuberculosis. MGIT drug sensitivity test (DST)     │         │
│ results are sensitive of the first-line drugs      │ results are sensitive of the first-line drugs      │         │
│ (isoniazid, streptomycin, rifampicin and           │ (isoniazid, streptomycin, rifampicin and           │         │
│ ethambutol)                                        │ ethambutol)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age 18 years-65 years old                          │ Age 18 years-65 years old                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Males or non-pregnant, non-nursing females         │ Males or non-pregnant, non-nursing females         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum or plasma aminotransferases (AST, ALT) less  │ Serum or plasma aminotransferases (AST, ALT) less  │     100 │
│ than 3 times the upper limit of normal             │ than 3 times the upper limit of normal             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum or plasma total bilirubin less than or equal │ Serum or plasma total bilirubin less than or equal │     100 │
│ to 2.5 times the upper limit of normal             │ to 2.5 times the upper limit of normal             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum or plasma creatinine level less than or      │ Serum or plasma creatinine level less than or      │     100 │
│ equal to 2 times the upper limit of normal         │ equal to 2 times the upper limit of normal         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum or plasma potassium level greater than or    │ Serum or plasma potassium level greater than or    │     100 │
│ equal to 3.5 meq/L                                 │ equal to 3.5 meq/L                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin level of 7.0 g/dL or greater            │ Hemoglobin level of 7.0 g/dL or greater            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count of 100,000/mm3 or greater           │ Platelet count of 100,000/mm3 or greater           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For women of childbearing potential, a negative    │ For women of childbearing potential, a negative    │     100 │
│ pregnancy test is required during screening        │ pregnancy test is required during screening        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Provides written informed consent                  │ Provides written informed consent                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willingness and ability to attend scheduled        │ Willingness and ability to attend scheduled        │     100 │
│ follow-up visits and undergo study assessments     │ follow-up visits and undergo study assessments     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Tuberculosis resistant to any of the study drugs   │ Tuberculosis resistant to any of the study drugs   │     100 │
│ (isoniazid, rifampin, EMB, PZA, CFZ, Pto)          │ (isoniazid, rifampin, EMB, PZA, CFZ, Pto)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unable to take oral medications                    │ Unable to take oral medications                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of allergy or intolerance to any of the    │ History of allergy or intolerance to any of the    │     100 │
│ study drugs                                        │ study drugs                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum aminotransferase (AST or ALT) 3x upper limit │ Serum aminotransferase (AST or ALT) 3x upper limit │     100 │
│ of normal or higher                                │ of normal or higher                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing females, or plan to become     │ Pregnant or nursing females, or plan to become     │     100 │
│ pregnant or nurse during the study period          │ pregnant or nurse during the study period          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Males planning to conceive a child during the      │ Males planning to conceive a child during the      │     100 │
│ study or within 6 months of cessation of treatment │ study or within 6 months of cessation of treatment │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any treatment directed against active tuberculosis │ Any treatment directed against active tuberculosis │     100 │
│ within 6 months preceding initiation of study      │ within 6 months preceding initiation of study      │         │
│ drugs                                              │ drugs                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Suspected or documented tuberculosis involving the │ Suspected or documented tuberculosis involving the │     100 │
│ central nervous system and/or bones and/or joints, │ central nervous system and/or bones and/or joints, │         │
│ and/or miliary tuberculosis and/or pericardial     │ and/or miliary tuberculosis and/or pericardial     │         │
│ tuberculosis                                       │ tuberculosis                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV infected                                       │ HIV infected                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HBV infected or HCV infected (these increase the   │ HBV infected or HCV infected (these increase the   │     100 │
│ risk of TB-drug induced hepatotoxicity)            │ risk of TB-drug induced hepatotoxicity)            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Weight less than 40.0 kg                           │ Weight less than 40.0 kg                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known allergy or intolerance to any of the study   │ Known allergy or intolerance to any of the study   │     100 │
│ medications                                        │ medications                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Individuals will be excluded from enrollment if,   │ Individuals will be excluded from enrollment if,   │     100 │
│ at the time of enrollment, their M. tuberculosis   │ at the time of enrollment, their M. tuberculosis   │         │
│ isolate is already known to be resistant to any of │ isolate is already known to be resistant to any of │         │
│ the study drugs                                    │ the study drugs                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other medical conditions, that, in the             │ Other medical conditions, that, in the             │     100 │
│ investigator's judgment, make study participation  │ investigator's judgment, make study participation  │         │
│ not in the individual's best interest              │ not in the individual's best interest              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current or planned incarceration or other          │ Current or planned incarceration or other          │     100 │
│ involuntary detention                              │ involuntary detention                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Having participated in other clinical studies with │ Having participated in other clinical studies with │     100 │
│ dosing of investigational agents within 8 weeks    │ dosing of investigational agents within 8 weeks    │         │
│ prior to trial start or currently enrolled in an   │ prior to trial start or currently enrolled in an   │         │
│ investigational study that includes treatment with │ investigational study that includes treatment with │         │
│ medicinal agents. Subjects who are participating   │ medicinal agents. Subjects who are participating   │         │
│ in observational studies or who are in a follow up │ in observational studies or who are in a follow up │         │
│ period of a trial that included drug therapy may   │ period of a trial that included drug therapy may   │         │
│ be considered for inclusion                        │ be considered for inclusion                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ QTcF \> 500 msec                                   │ QTcF > 500 msec                                    │      97 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria                                      │   Score │
╞══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 65 Years                │ Age 18 years-65 years old                          │      38 │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                │ Hemoglobin level of 7.0 g/dL or greater            │      39 │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ a.Effective birth control methods: i.A double    │ Having participated in other clinical studies with │      40 │
│ contraceptive method should be used as follows:  │ dosing of investigational agents within 8 weeks    │         │
│ ii.Double barrier method which can include any 2 │ prior to trial start or currently enrolled in an   │         │
│ of the following: a male condom, diaphragm,      │ investigational study that includes treatment with │         │
│ cervical cap, or female condom (male and female  │ medicinal agents. Subjects who are participating   │         │
│ condoms should not be used together); or         │ in observational studies or who are in a follow up │         │
│ iii.Barrier method (one of the above) combined   │ period of a trial that included drug therapy may   │         │
│ with hormone-based contraceptives or an intra-   │ be considered for inclusion                        │         │
│ uterine device for the female subject/partner;   │                                                    │         │
│ iv.and are willing to continue practicing birth  │                                                    │         │
│ control methods throughout treatment and for 6   │                                                    │         │
│ months (both male and female subjects) after the │                                                    │         │
│ last dose of study medication or discontinuation │                                                    │         │
│ from study medication in case of premature       │                                                    │         │
│ discontinuation                                  │                                                    │         │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Laboratory parameters done at or within 14 days  │ Pulmonary lesion consistent with TB by             │      47 │
│ prior to screening                               │ radiological examination                           │         │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of child-bearing potential who are not     │ For women of childbearing potential, a negative    │      49 │
│ surgically sterilized must agree to practice a   │ pregnancy test is required during screening        │         │
│ barrier method of contraception or abstain from  │                                                    │         │
│ heterosexual intercourse during study drug       │                                                    │         │
│ treatment                                        │                                                    │         │
╘══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 84
Average Levenshtein Ratio of individual lines: 91.94444444444444
OverAll Ratio: 87.97222222222223
